Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Actylis launches with focus on raw materials and performance ingredients for life sciences and specialty chemicals 

By Brian Buntz | September 26, 2022

ActylisThe conglomerate Actylis made its debut today. The new brand integrates specialty ingredient maker Aceto with 10 specialty ingredient manufacturing and sourcing companies.

The Port Washington, New York–based company will serve customers in various industries, including pharmaceutical and biopharmaceutical companies. It will also offer materials to companies specializing in nutrition, cosmetics, agriculture and specialty chemicals markets.

Among the specialty ingredient manufacturing and sourcing companies integrated in the merger are A&C, A&C Bio Buffer, Biotron Laboratories, Cascade Chemistry, Finar, Inter-Actifs, IsleChem, Pharma Waldhof, Syntor Fine Chemicals and Talus.

Actylis

Actylis bio buffer facility. [Picture: Keith Wiseman]

The consolidation of those companies plus Aceto “enables us to offer customers across diverse locations and industries highly flexible, customized solutions addressing their specific needs while assuring reliable on-time delivery of the high-quality ingredients essential to their success,” said Gilles Cottier, Actylis CEO.

“If we can’t manufacture it, we’ll source it and if we can’t source it, we’ll manufacture it,” quipped Cottier in a media briefing.

The new company aims to tap its breadth to improve product availability for customers who have struggled with supply chain challenges during the pandemic. “As we face the most recent challenges, we’ve been able to navigate the supply chain and figure out how we ensure that our customers see the least amount of disruption possible,” said Edward Roullard, senior vice president of marketing and operations, in a media briefing. “Because we’ve got such a large sourcing network, if we had a plant in China that suddenly couldn’t operate because of COVID, chances are we had another supplier already qualified in India that we could substitute if that would work for the customer.”

The company manages 15,000 international shipments each year and has 50 sourcing specialists worldwide.

The breadth of the company’s network will help it to focus on supply chain resiliency and move away from concepts that no longer are useful, Roullard said. “Lean has been a keyword over the past 20–25 years. Lean is great until something goes wrong,” he noted. “And I think we’re tending to see more and more disruption, which throws a wrench into the lean strategy.”

“We don’t believe the disruptions will end and lean in the end will cost us more than the immediate return we might be able to save,” Roullard added.

Actylis has more than 850 employees in 10 countries with backgrounds in specialty manufacturing or ingredient sourcing. The company’s sourcing network includes more than 1,000 suppliers and 300 strategic relationships.

Before announcing the formation of Actylis, the company conducted extensive customer, industry and internal stakeholder research.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].

Tell Us What You Think! Cancel reply

Related Articles Read More >

Apiject Logo
Apiject to open new injectable drug manufacturing facility in North Carolina
BD Neopak XtraFlow glass prefillable syringe (1)
BD to invest $110M to support prefilled syringe production, pharma supply chain
Samsung Biologics GSK Rockville Maryland plant (1)
Samsung Biologics acquires GSK manufacturing site
This is the logo of Novartis.
Novartis breaks ground on North Carolina facility
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE